Trials / Unknown
UnknownNCT04283539
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 238 (estimated)
- Sponsor
- National Jewish Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | systemic corticosteroid or biologic | Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice) |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2024-06-01
- Completion
- 2025-02-01
- First posted
- 2020-02-25
- Last updated
- 2023-11-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04283539. Inclusion in this directory is not an endorsement.